The analysis examined overall program counts as well as distribution by development stage, drug modality, and therapeutic area. Growth in early-stage development was observed across multiple countries ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
Hosted on MSN
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data readout in early 2026; ...
Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results